Cirius Highlights New Clinical Data for CIR-0602K as a Potential Treatment for Type 2 Diabetes

A new approach to tackling insulin resistance

Cirius Therapeutics has announced that new clinical data for its investigational drug CIR-0602K will be presented at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans.

The presentation will focus on how CIR-0602K may help address one of the biggest challenges in type 2 diabetes management: insulin resistance.

While several new diabetes treatments have entered the market over the past decade, many patients still struggle to achieve recommended blood sugar targets. Cirius believes that directly targeting insulin resistance could help close this treatment gap and improve outcomes for millions of people living with diabetes.

Why many patients still struggle with blood sugar control

Type 2 diabetes affects an estimated 35 million people in the United States alone.

Although medications such as GLP-1 receptor agonists have improved treatment options, a large percentage of patients continue to miss their HbA1c goals. HbA1c is a key measure of long-term blood sugar control and is commonly used to assess diabetes management.

Recent studies suggest that more than half of people with type 2 diabetes in real-world settings do not achieve the commonly recommended HbA1c target of less than 7%.

One reason for this may be persistent insulin resistance.

Even when patients successfully manage factors such as excess weight, underlying insulin resistance can continue to make blood sugar control difficult.

What is CIR-0602K?

CIR-0602K is a next-generation insulin sensitizer being developed as a once-daily oral treatment.

Unlike many existing diabetes therapies that primarily focus on increasing insulin production or improving insulin signaling indirectly, CIR-0602K targets a key driver of metabolic dysfunction at the cellular level.

The drug works by selectively inhibiting the mitochondrial pyruvate carrier (MPC), a protein involved in cellular energy metabolism.

By targeting MPC, CIR-0602K aims to:

• Reduce mitochondrial dysfunction
• Lower metabolic inflammation
• Improve insulin sensitivity
• Enhance blood sugar control

Researchers believe this mechanism may help address the root causes of insulin resistance rather than simply managing its symptoms.

How the drug works

Mitochondria are often referred to as the powerhouses of cells because they generate energy needed for normal cellular function.

When mitochondrial function becomes impaired, insulin resistance can develop and worsen over time.

CIR-0602K is designed to restore healthier metabolic activity by reprogramming how cells use energy.

This approach may help lower blood glucose levels while simultaneously reducing circulating insulin levels, an outcome that many diabetes specialists consider particularly valuable.

By improving insulin sensitivity, the drug may help the body use insulin more effectively and reduce the burden on insulin-producing cells.

Clinical findings presented at ADA

The poster presentation at ADA will highlight evidence showing that CIR-0602K has the potential to improve insulin sensitivity and glycemic control in people with type 2 diabetes.

According to Cirius, previous clinical studies have demonstrated benefits even among patients who were already receiving standard treatments, including GLP-1 therapies.

Researchers believe that adding CIR-0602K to existing treatment regimens could help more patients achieve their HbA1c targets.

The company also suggests that improving insulin resistance may work synergistically with weight-loss therapies, potentially enhancing overall metabolic health.

What previous studies have shown

CIR-0602K has already completed seven clinical trials in the United States.

These studies include:

• A 52-week Phase 2b study involving 392 participants with metabolic dysfunction-associated steatohepatitis (MASH), with and without type 2 diabetes
• A 28-day Phase 2a study involving 129 participants with type 2 diabetes

Across these studies, researchers observed several encouraging outcomes.

Participants experienced:

• Reduced HbA1c levels
• Lower insulin levels
• Improvements in insulin sensitivity
• Reduced liver injury markers
• Improvements in MASH-related outcomes

Importantly, some benefits were observed even when CIR-0602K was used alongside GLP-1 therapies.

Potential benefits beyond type 2 diabetes

Although the current presentation focuses on type 2 diabetes, researchers believe the drug's mechanism may have applications in several other metabolic conditions.

Cirius is currently evaluating CIR-0602K in type 1 diabetes through an ongoing Phase 2a clinical study.

The study began enrolling participants in early 2026 with support from Breakthrough T1D.

The company is also exploring opportunities in gestational diabetes mellitus (GDM).

Recently, the Gates Foundation awarded funding to support research into whether CIR-0602K could be used as a postpartum treatment for women with a history of gestational diabetes.

These additional development programs reflect growing interest in the role of mitochondrial dysfunction and insulin resistance across multiple disease areas.

Potential role in obesity and metabolic health

Beyond diabetes, preclinical studies suggest CIR-0602K may provide benefits related to body composition and metabolic health.

Researchers observed:

• Increased lean muscle mass
• Improved muscle strength
• Better muscle metabolic function
• Healthier fat tissue characteristics

Studies also showed favorable changes in adipose tissue biology, including the conversion of metabolically unhealthy fat into more metabolically active tissue.

When combined with GLP-1 and GLP-1/GIP therapies such as tirzepatide, these effects appeared even more pronounced.

This raises the possibility that CIR-0602K could eventually become part of combination treatment strategies for obesity and cardiometabolic disease.

A different approach from older insulin sensitizers

First-generation insulin sensitizers, such as pioglitazone, have demonstrated effectiveness in improving insulin sensitivity. However, concerns about side effects have limited their broader use.

Cirius believes CIR-0602K may offer many of the metabolic benefits associated with older insulin sensitizers while avoiding some of their unwanted effects.

The drug achieves this by selectively targeting MPC without activating PPAR-gamma, a pathway linked to several side effects associated with earlier therapies.

This distinction could make CIR-0602K an attractive option for long-term treatment if future studies continue to support its safety and efficacy profile.

What comes next?

The upcoming ADA presentation will provide researchers, clinicians, and industry experts with a closer look at the growing body of evidence supporting CIR-0602K.

As development continues, Cirius hopes the drug can become an important addition to the diabetes treatment landscape, particularly for patients whose insulin resistance remains poorly controlled despite existing therapies.

Further clinical studies will be needed to confirm long-term benefits and determine how the drug fits alongside current standards of care.

Final takeaway

CIR-0602K represents a different approach to treating type 2 diabetes by directly targeting mitochondrial dysfunction and insulin resistance.

Clinical studies to date suggest the investigational therapy may improve blood sugar control, lower insulin levels, and complement existing treatments such as GLP-1 therapies.

With ongoing research in type 2 diabetes, type 1 diabetes, obesity, MASH, and gestational diabetes, the drug has the potential to address multiple metabolic disorders driven by insulin resistance.

As more data emerge, CIR-0602K could become an important new tool for helping patients achieve better metabolic health and improved long-term outcomes.